Severe aortic stenosis (AS) is frequently present in the ageing population and is related to mortality and morbidity. Traditionally, this disease has been treated with surgical aortic valve replacement (SAVR); however, during the last decade the field has been revolutionised by the less invasive transcatheter aortic valve implantation (TAVI). The number of TAVI procedures is increasing rapidly and, as the boundaries of TAVI are continuously pushed, there is an increased need for knowledge on how to deal with comorbidities.
Concomitant coronary artery disease (CAD) is a frequent comorbidity observed in up to 50% of patients selected for TAVI1. The ...
Sign in to read and download the full articleForgot your password?
Join us for free and access thousands of articles from EuroIntervention, as well as presentations, videos, cases from PCRonline.com